Results of a Phase 1 trial of Seattle Genetics' lead drug candidate brentuximab vedotin, also known as SGN-35. sponsored by the drug manufacturer, suggest that the much-hyped drug may warrant indications in patients whose disease has proven refractory.
Of the 45 patients who took part in the open-label, multicenter dose-escalation study, 11 experienced complete remission, while another 6 experienced partial remission. In 19 patients their disease remained stable, and in 8 patients their disease progressed.
CANCER TYPE(S)
CD30 positive refractory lymphomas (Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma)
TREATMENT TYPE(S)
Antibody drug conajugate
WHERE WAS THIS STUDY PUBLISHED?
New England Journal of Medicine/em>
Source
NEJM
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
